Previous 10 | Next 10 |
Introduction Think about it: the world is having a health crisis and what do we do? We created the largest global collapse since 1929! And as noted in prior columns , we are now at a point where nobody wanted to go: we must continually ask: do we continue the global “lockdownȁ...
In a note, Evercore ISI's Joshua Schimmer says Moderna's (NASDAQ: MRNA ) COVID-19 vaccine, mRNA-1273, is unlikely to be the best of the bunch but may wind up being "good enough" to get the first regulatory nod, adding that other candidates appear poised to offer higher immunogenicity, fewer ...
Safe-T Group (NASDAQ: SFET ) +44% as its wholly owned subsidiary, NetNut has expanded into a new market with the signing of agreements with three leading companies operating in the consumer VPN sector. More news on: Safe-T Group Ltd, Surface Oncology, Inc., Cheetah Mobile Inc., St...
Kindred Biosciences (NASDAQ: KIN ) inks an agreement with Vaxart (NASDAQ: VXRT ) to manufacture its oral COVID-19 vaccine candidate at its Burlingame, CA site. Its contract development and manufacturing efforts are managed by subsidiary Centaur Biopharmaceutical Services. More news ...
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechno...
SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for C...
The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19 . And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs. Some investors could be temp...
The stock of Emergent BioSolutions (NYSE: EBS) has been on fire of late. Year to date, shares are up by 56.6%, while the S&P 500 is down by 9.3%. What's behind Emergent's strong performance amid a highly volatile stock market and challenging economic conditions? The company h...
Vaxart (NASDAQ: VXRT ): Q1 GAAP EPS of -$0.02 beats by $0.02 . More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Lead Vaccine Candidates for COVID-19 are Highly Immunogenic in Preclinical Testing COVID-19 Phase 1 Clinical Study Planned for 2H20 SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage b...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...